Glyceryl Trinitrate Bristol Laboratories

Glyceryl Trinitrate Bristol Laboratories is a prescription medication that contains the active ingredient glyceryl trinitrate. The product is supplied in a sublingual dosage form, with strength not specified in the available data. It is manufactured for the EU market and belongs to the organic nitrate class of anti‑anginal agents. It is intended for use to manage episodes of chest pain related to reduced blood flow to the heart.

Glyceryl Trinitrate Bristol Laboratories is primarily prescribed for conditions where the heart requires reduced oxygen demand.

- Acute relief of angina pectoris episodes. - Prevention of angina attacks during physical exertion or emotional stress. - Management of acute myocardial ischemia in emergency settings. - Adjunct therapy in diagnostic procedures that may provoke coronary spasm. - Short‑acting sublingual treatment to rapidly lower cardiac preload. - Use in combination with long‑acting nitrate regimens for chronic angina control.

The safety profile of Glyceryl Trinitrate Bristol Laboratories reflects the typical effects observed with sublingual organic nitrates.

Common: - Headache, often described as throbbing, due to vasodilation. - Flushing or warmth in the face and neck. - Dizziness or light‑headedness, especially when standing quickly. - Nausea or mild gastrointestinal discomfort. - Sweating (diaphoresis) during an episode. - Feeling of palpitations or rapid heartbeat. - Dry mouth or metallic taste.

Serious: - Severe hypotension leading to fainting or shock. - Rapid or irregular heart rhythm (arrhythmia). - Methemoglobinemia, a rare blood disorder affecting oxygen transport. - Chest pain that does not improve with repeat dosing (possible nitrate tolerance). - Allergic reaction such as rash, itching, or swelling. - Severe headache unresponsive to over‑the‑counter analgesics.

When prescribing Glyceryl Trinitrate Bristol Laboratories, clinicians consider several precautionary factors to minimize risk and ensure appropriate use.

- Assess blood pressure before administration; avoid use in patients with severe hypotension. - Review patient history for recent use of phosphodiesterase‑5 inhibitors, as combined effect may cause dangerous blood pressure drops. - Evaluate for known hypersensitivity to organic nitrates or any component of the formulation. - Consider dose adjustment in patients with hepatic impairment, given altered metabolism. - Counsel patients on proper sublingual technique to prevent swallowing and reduced efficacy. - Monitor for signs of tolerance with long‑term therapy and rotate dosing intervals as recommended.

Glyceryl Trinitrate Bristol Laboratories can interact with other medicines, affecting blood pressure or nitrate metabolism.

Avoid: - Concomitant use with phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) – may cause profound hypotension. - Simultaneous administration of other potent vasodilators (e.g., hydralazine, nitroprusside) – risk of additive blood pressure lowering. - Use with alcohol in excess – can enhance dizziness and hypotensive effects.

Use with caution: - Beta‑blockers or calcium‑channel blockers – monitor cardiovascular response. - Antihypertensive agents such as ACE inhibitors or ARBs – adjust dosing as needed. - General anesthetics containing volatile agents – may potentiate vasodilatory response.